Br[C:2]1[N:3]=[C:4]([C:7]([CH3:9])=[CH2:8])[S:5][CH:6]=1.[F:10][C:11]([F:50])([F:49])[C:12]1[CH:13]=[C:14]([C@H:22]2[O:26][C:25](=[O:27])[N:24]([CH2:28][C:29]3[CH:34]=[C:33]([C:35]([F:38])([F:37])[F:36])[CH:32]=[CH:31][C:30]=3B3OC(C)(C)C(C)(C)O3)[C@H:23]2[CH3:48])[CH:15]=[C:16]([C:18]([F:21])([F:20])[F:19])[CH:17]=1.C([O-])([O-])=O.[K+].[K+]>C1COCC1>[F:50][C:11]([F:10])([F:49])[C:12]1[CH:13]=[C:14]([C@H:22]2[O:26][C:25](=[O:27])[N:24]([CH2:28][C:29]3[CH:34]=[C:33]([C:35]([F:36])([F:37])[F:38])[CH:32]=[CH:31][C:30]=3[C:2]3[N:3]=[C:4]([C:7]([CH3:9])=[CH2:8])[S:5][CH:6]=3)[C@H:23]2[CH3:48])[CH:15]=[C:16]([C:18]([F:19])([F:21])[F:20])[CH:17]=1In a tube were placed 4-bromo-2-isopropenyl-1,3-thiazole (20 mg, 0.097 mmol), (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-4-methyl-3-[2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5-(trifluoromethyl)benzyl]-1,3-oxazolidin-2-one (29.4 mg, 0.0492 mmol), THF (340 μL), 1M aqueous K2CO3 (340 μL), and 1,1-bis(di-t-butylphosphino)ferrocene palladium chloride (3.2 mg, 4.9×10−3 mmol). The mixture was degassed with N2. The tube was sealed and heated at 100° C. for 1.5 hours. The reaction was then cooled to room temperature, diluted with EtOAc (50 mL), and washed with water and brine (15 mL each). The organic layer was dried over Na2SO4, filtered, and concentrated. Purification of the residue by flash chromatography on silica gel (5 to 25% EtOAc/hexanes) and then by PTLC (90% CH2Cl2/hexanes) afforded (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(2-isopropenyl-1,3-thiazol-4-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one. Rf=0.16 (15% EtOAc/hexanes). LCMS=595.1 (M+1)+. 1H NMR (CD2Cl2, 500 MHz) δ 7.90 (s, 1H), 7.64-7.76 (m, 5H), 7.38 (s, 1H), 5.89 (s, 1H), 5.60 (d, J=8.1 Hz, 1H), 5.37 (d, J=1.2 Hz, 1H), 4.99 (d, J=16.0 Hz, 1H), 4.66 (d, J=16.0 Hz, 1H), 3.94 (m, 1H), 2.25 (s, 3H), 0.59 (d, J=6.4 Hz, 3H).
Loading…